Cancer Age Country 1st diagnostic Status
Breast Cancer HR 47 France 2008 Tumour regression
See Christine's report

Christine, Breast Cancer HR

Age Country 1st diagnostic Status
47 France 2008 Tumour regression

In July 2008 the patient was diagnosed with a breast cancer ER+ / PR+ / HER2+.

I'm a patient

I’m interested in this case and would like to receive more information.

See Christine's report

Detailed report

  • Jul 2008


    The patient was diagnosed with a metastatic breast cancer

    Relapse in 2013

    Biomarkers already tested:

    – 2008: ER+ / PR+ / HER2+
    – 2013 : HER2+ / HR+
    – 2014: skin metastasis (HER2 negative)

  • Previous treatment

    The patient was successively treated with
    – Taxol / herceptin / tykerb
    – Aromasin / herceptin
    – Herceptin / xeloda / gemzar
    – Taxol / caelyx / endoxan
    – Femara / afinitor / faslodex / xeloda / navelbine
    – Halaven

  • Jan 2016

    In January 2016, the oncologist asked for an OncoDEEP testing on one of the metastases.
    – PIK3CA and ESR1 variants identified
    – IHC: PTEN and P4EBP1 expression


    Recommended treatments:

    – Approved for breast cancer : Dual PIK3CA/mTOR inhibitors
    – March 2016 : faslodex (ESR1 variant) + palbociclib (PhosphoRB)

    Based on our recommandations, the oncologist decided to treat the patient with faslodex + palbociclib.

  • Mar 2016

    Prior the first cycle of therapy, blood samples were collected at the baseline. OncoTRACE analysis identified 5 variants, thereby giving ‘real-time’ and complete picture of cancer. Endocrine-therapy-resistant ESR1 variant has been found and has been likely developed through the different previous therapies. Indeed these alterations confer a selective advantage to tumor cells when under the pressure of anti-ER therapy. This variant has not been detected in the initial solid biopsy analysis, most probably because of the heterogeneity of the disease. These results point out the importance of performing both analysis, liquid and solid, in a metastatic disease.

  • Sep 2016

    After one month a regression of the tumor was observed by the oncologist. A new OncoTRACE has been performed in September 2016, and we observed a reduction of the percentage of presence of the 5 variants. This encouraging results have been confirmed afterwards by the oncologist that observed a decrease in the tumor markers.

  • Current status

    Sadly Christine passed away recently. Though our solutions helped her to come out of palliative care and enjoy more than a year with a good quality of life, her cancer was too advanced to achieve remission.

The testimonial


I needed to be led through the best treatment options which would provide a real effectiveness while preserving her a good quality of life.

Used solutions

  • x 1
  • Cost-effective solution combining DNA and protein analysis of a solid tumour sample
    More about OncoDEEP

Case reports